Nuvilex Inc. (NASDAQ:PMCB) Short Interest Update

Nuvilex Inc. (NASDAQ:PMCB) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 177,318 shares, a growth of 181.9% from the December 31st total of 62,893 shares. Based on an average daily trading volume, of 459,349 shares, the short-interest ratio is presently 0.4 days. Currently, 2.0% of the company’s stock are sold short. Currently, 2.0% of the company’s stock are sold short. Based on an average daily trading volume, of 459,349 shares, the short-interest ratio is presently 0.4 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Nuvilex in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Nuvilex Trading Down 5.2%

Nuvilex stock opened at $0.90 on Thursday. Nuvilex has a 12 month low of $0.63 and a 12 month high of $1.90. The stock has a fifty day simple moving average of $0.86 and a two-hundred day simple moving average of $0.93. The firm has a market cap of $9.11 million, a price-to-earnings ratio of -0.65 and a beta of 0.04.

Nuvilex (NASDAQ:PMCB) last released its quarterly earnings data on Thursday, December 18th. The company reported ($0.32) EPS for the quarter.

Insiders Place Their Bets

In related news, CEO Joshua Silverman acquired 40,000 shares of the stock in a transaction on Wednesday, January 7th. The stock was acquired at an average price of $0.83 per share, for a total transaction of $33,200.00. Following the completion of the purchase, the chief executive officer owned 416,250 shares of the company’s stock, valued at $345,487.50. This represents a 10.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders purchased 110,000 shares of company stock worth $89,000. 10.33% of the stock is owned by company insiders.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.